Hormonal therapy, targeting ER [16,17], and small-molecule and antibody therapies, targeting ErbB2 [11,18,19], have significantly improved treatments for ER+ and HER2+ breast cancer patients. This evidence concerns the gene ESR1 and breast cancer.